Baseline characteristics of patients in SWEFOT study treated with methotrexate in monotherapy
| Overall (n=405) | In model* (n=322) | |
|---|---|---|
| Women, n (%) | 318 (71%) | 228 (71%) |
| Age (years), median (IQR) | 57 (44–64) | 57 (44–63) |
| Cigarette smoking status | ||
| Current smokers, n (%) | 87 (25%) | 82 (25%) |
| Past smokers, n (%) | 140 (39%) | 126 (39%) |
| Never smokers, n (%) | 127 (36%) | 114 (36%) |
| Symptom duration (months), median (IQR) | 6 (4–8) | 6 (4–9) |
| Rheumatoid factor positive, n (%) | 175 (49%) | 145 (51%) |
| Anti-CCP antibody positive, n (%) | 246 (64%) | 205 (64%) |
| Concurrent prednisolone, n (%) | 55 (14%) | 38 (12%) |
| Concurrent NSAIDs, n (%) | 248 (61%) | 206 (64%) |
| HAQ score, median (IQR) | 1.1 (0.8–1.5) | 1.1 (0.8–1.6) |
| DAS28, median (IQR) | 5.7 (4.9–6.3) | 5.7 (5.0–6.4) |
| SDAI, median (IQR) | 32.9 (25.1–41.8) | 32.9 (25.1–42.7) |
| CDAI, median (IQR) | 29.6 (23.2–38.0) | 29.6 (23.0–38.7) |
anti-CCP, anti-cyclic citrullinated peptide antibody; CDAI, Clinical Disease Activity Index; HAQ, Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; SDAI, Simple Disease Activity Index.